BIOXPRESS THERAPEUTICS
Located in Geneva, Switzerland, BioXpress Therapeutics SA is a premier provider of high-quality biologic APIs (MAb and MAb-like biosimilars) for unmet need indications, such as cancer, inflammation and autoimmunity. BioXpress Therapeutics is focused on developing biosimilar monoclonal antibodies in many different countries. BioXpress Therapeutics currently has five programs in development, two of which are partnered with worldwide rights. See their pipeline for more information. BioXpress Thera... peutics is activity seeking alliances with other biopharmaceutical companies and health organizations to accelerate the development of biosimilar therapeutics. They are already engaged in collaborations with partners from various countries and would like to hear from you. Please CONTACT US for pipeline partnership opportunities. The MAb-based drug market is one of the fastest growing categories of the biopharmaceuticals industry. These products are of high value for pharmaceutical industry, both in research as well as drug development activities. By 2011, biologics worth $18 billion USD in annual sales are expected to lose patent protection in developed countries and by 2018, over half of the approved MAbs will have lost patent protection, thus increasing the potential market size by a factor of at least 5 fold. The worldwide market for copies of biotech medicines will grow to $3.7 billion by 2015, from just $243 million in 2010, as a raft of branded drugs lose patent cover. Of those, monoclonal antibody therapeutics are forecasted to grow at a CAGR approaching 10% over the next five years, driven largely by positive results in the clinic. Cancers and immune-related inflammatory diseases will continue to be leading markets for MAbs during the five-year forecast period. 2010 was the first time in human history when nine human medicinal brands had sales exceeding $3 billion USD. Of these nine drugs, seven were biologics and of these, 6 were MAbs or MAb derivatives. BioXpress Therapeutics is rapidly advancing its biosimilars pipeline.
BIOXPRESS THERAPEUTICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2010-01-01
Address:
Plan-les-ouates, Geneve, Switzerland
Country:
Switzerland
Website Url:
http://www.bioxpress.com
Total Employee:
1+
Status:
Active
Contact:
41 22 884 86 53
Email Addresses:
[email protected]
Technology used in webpage:
SPF SSL By Default Domain Not Resolving Amazon Amazon Ohio Region
Similar Organizations
ActoBio Therapeutics
ActoBio Therapeutics develops therapeutic agents that treat a number of diseases, primarily on disease areas with high unmet needs.
Official Site Inspections
http://www.bioxpress.com
- Host name: ec2-3-13-51-11.us-east-2.compute.amazonaws.com
- IP address: 3.13.51.11
- Location: Columbus United States
- Latitude: 39.9653
- Longitude: -83.0235
- Metro Code: 535
- Timezone: America/New_York
- Postal: 43215

More informations about "BioXpress Therapeutics"
About Us - BioXpress Therapeutics
About BioXpress Therapeutics. BioXpress Therapeutics SA is exclusively focused on the development of biosimilars.With a philosophy that everyone should have access to high quality โฆSee details»
BioXPress Therapeutics - BioAlps
Premier partner for high-quality biosimilar monoclonal antibodies for unmet need indications such as cancer, inflammation and autoimmunity, including adaptive immunity. Target indication for โฆSee details»
Home - BioXpress Therapeutics
BioXpress Therapeutics SA is a premier partner for high-quality biosimilar monoclonal antibodies for unmet need indications such as cancer, inflammation and autoimmunity, including adaptive โฆSee details»
Board of Directors - BioXpress Therapeutics
Luc-Alain Savoy, PhD Chairman. Dr. Savoy is co-founder and chairman of BioXpress Therapeutics SA. Previously, he co-founded in 1991 M-Scan SA, a contract research โฆSee details»
Press Releases - BIO
Jun 16, 2025 Press Releases Bio.News Blog Letters, Testimony & Comments Amicus Briefs Industry Analysis Reports Biotech Jobs Economic Development Best Practices Issue Briefs โฆSee details»
BioXpress Therapeutics - PitchBook
When was BioXpress Therapeutics founded? BioXpress Therapeutics was founded in 2008. Where is BioXpress Therapeutics headquartered? BioXpress Therapeutics is headquartered โฆSee details»
About BIO 2025 - BIO International Convention 2024
BIO 2025 will be held in Boston, MA. Stand up for science-the world can't wait for biotechnology innovation. June 16-19, 2025. ... Whether you work at a public pharmaceutical company, โฆSee details»
BioXpress Management Team - CB Insights
Grupo Elfa. Grupo Elfa specializes in healthcare supply chain services, operating within the healthcare sector. The company offers a broad portfolio of products and services that โฆSee details»
BioPress Publication
Bio Press Publication Helping Authors Turn Ideas into Reality Your Trusted Partner in Publishing & Printing. At BioPress Publishing, we provide comprehensive book publishing, on-demand โฆSee details»
BioXpress Therapeutics - Crunchbase Company Profile & Funding
Located in Geneva, Switzerland, BioXpress Therapeutics SA is a premier provider of high-quality biologic APIs (MAb and MAb-like biosimilars) for unmet need indications, such as cancer, โฆSee details»
Biotechnology Industry Organization to become Biotechnology โฆ
Name change to occur in early 2016. Organization continues to be known as BIO. Philadelphia, PA (June 17, 2015) โ BIOโs new Board Chair, Ron Cohen, CEO of Acorda Therapeutics, โฆSee details»
Biotechnology Innovation Organization | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Press Releases. Letters, โฆSee details»
BIO International Convention | June 16-19, 2025 | Boston
Discover the companies presenting at BIO 2025,. Explore innovations across oncology, immunology, regenerative medicine, and more. June 16-19, 2025. Boston Convention & โฆSee details»
Biotechnology Innovation Organization
Learn about BIO, register for events and explore member services. The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for โฆSee details»
BIO Appoints Veteran Communications Leader Sarah Alspach as โฆ
Dec 9, 2024 Today, the Biotechnology Innovation Organization (BIO) named Sarah Alspach as its new executive vice president and chief communications officer. Alspach, a communications โฆSee details»
Bio-Techne and USP Announce Collaboration to Accelerate โฆ
1 day ago MINNEAPOLIS, June 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that โฆSee details»
BIO Announces Dedicated Focus on Human Health and โฆ
Washington, DC, May 28, 2025 โ The Biotechnology Innovation Organization (BIO) today announced plans to dedicate its focus entirely to human health and to transition the work of its โฆSee details»
BIO International Convention | June 16-19, 2025 | Boston
May 29, 2025 See the schedule of events for the 2025 BIO International Convention, June 16-19, 2025 at the Boston Convention and Exhibition Center.See details»
Regeneron Announces First-of-its-Kind Donation Matching
10 hours ago Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications. TARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) โฆSee details»
News | BIO
Press Releases Bio.News Blog Letters, ... The Biotechnology Innovation Organization (โBIOโ) respectfully moves the Court for leave to file an amicus brief in support of Plaintiffsโ response โฆSee details»